Ronald Natale on How Nurses Contribute to Patients' Quality of Life

Name: Ronald Natale on How Nurses Contribute to Patients' Quality of Life
Uploaded: 2016-09-16T01:44:03.000Z
Description: Oncology nurses are an important resource for patients with cancer when dealing with adverse effects that can be disruptive to quality of life.

September 15, 2016

Ronald Natale, MD

Video

Oncology nurses are an important resource for patients with cancer when dealing with adverse effects that can be disruptive to quality of life.

Ronald Natale, MD, of the Samuel Ocean Comprehensive Cancer Institute at Cedars-Sinai Medical Center, talks about the important role a nurse can play in improving the quality of life of patients with cancer.

When it comes to patients who have an EGRF-mutated lung cancer, adverse effects of the treatment can be annoying more than life-threatening. When it comes to dealing with skin, brittle hair/hair dye, and nail weakness, the oncology nurses become an important resource for patients, especially because many patients are on these therapies for a long time.

Related Content

Stress May Inhibit Immunotherapy’s Efficacy in Treating Cancer

November 28th 2023

Article

Finding ways to prevent and manage stress may be key to optimizing clinical outcomes in oncology.

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

November 15th 2023

Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

FDA Approves Repotrectinib for Adults With Advanced/Metastatic ROS1+ NSCLC

November 16th 2023

Article

Repotrectinib is now available to treat adults with advanced or metastatic non-small cell lung cancer that harbors a ROS1 fusion.

A Look Back at 2022 FDA Approvals in Oncology

January 2nd 2023

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Trilaciclib Snags ASCO Recommendation in Extensive-Stage Small Cell Lung Cancer

November 11th 2023

Article

New ASCO guidelines recommend trilaciclib for patients with untreated or previously treated extensive-stage small cell lung cancer who are receiving chemotherapy or chemoimmunotherapy.

High Price Tags and Implications: Cost of Care Is an Important Conversation in Cancer

November 8th 2023

Article

Screening for financial toxicity should be routine in cancer care, according to investigators.

Related Content

Stress May Inhibit Immunotherapy’s Efficacy in Treating Cancer

November 28th 2023

Article

Finding ways to prevent and manage stress may be key to optimizing clinical outcomes in oncology.

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

November 15th 2023

Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

FDA Approves Repotrectinib for Adults With Advanced/Metastatic ROS1+ NSCLC

November 16th 2023

Article

Repotrectinib is now available to treat adults with advanced or metastatic non-small cell lung cancer that harbors a ROS1 fusion.

A Look Back at 2022 FDA Approvals in Oncology

January 2nd 2023

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Trilaciclib Snags ASCO Recommendation in Extensive-Stage Small Cell Lung Cancer

November 11th 2023

Article

New ASCO guidelines recommend trilaciclib for patients with untreated or previously treated extensive-stage small cell lung cancer who are receiving chemotherapy or chemoimmunotherapy.

High Price Tags and Implications: Cost of Care Is an Important Conversation in Cancer

November 8th 2023

Article

Screening for financial toxicity should be routine in cancer care, according to investigators.